PharmaCieloPCLOF -4.35% Operating Margin % is 111.85% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, PharmaCielo ranks worse than 93.3% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. PharmaCielo's Operating Income for the
three
months ended in Dec. 2025 was $0.49 Mil. PharmaCielo's Revenue for the
three
months ended in Dec. 2025 was $0.44 Mil. Therefore, PharmaCielo's Operating Margin % for the quarter that ended in Dec. 2025 was 111.85%.
The historical rank and industry rank for PharmaCielo's Operating Margin % or its related term are showing as below:
PCLOF'
s Operating Margin % Range Over the Past 10 Years
Min: -4362.13 Med: -1295.32 Max: -161.06
Current: -161.06
PCLOF's Operating Margin % is ranked worse than 93.3% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs PCLOF: -161.06
PharmaCielo's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
PharmaCielo's Operating Income for the
three
months ended in Dec. 2025 was $0.49 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.12 Mil.
Warning Sign:
PharmaCielo Ltd had lost money in 92% of the time over the past 12quarters.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
PharmaCielo Operating Margin % Related Terms
PharmaCielo Operating Margin % Historical Data
* Premium members only.
The historical data trend for PharmaCielo's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Operating Margin % distribution charts can be found below:
* The bar in red indicates where PharmaCielo's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
PharmaCielo's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCielo (PCLOF) has a Operating Margin % of 111.85% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on PharmaCielo and its competitors. According to the industry distribution chart, PharmaCielo ranks #891 out of 955 companies in the Drug Manufacturers industry, placing it in the top 93.3%.
Is PharmaCielo's Operating Margin % too high?
PharmaCielo's current Operating Margin % is 111.85%. The Drug Manufacturers industry median Operating Margin % is 7.45. PharmaCielo's value of 111.85% is 1401.3% above this industry median. Based on the distribution chart, PharmaCielo ranks #891 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #891 out of 955 companies for Operating Margin %. This places PharmaCielo in the lower half of its industry. The industry median Operating Margin % is 7.45. PharmaCielo's value of 111.85% is 1401.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current Operating Margin % of 111.85% is 1401.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current Operating Margin % is 111.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.05 — trading 48.5% below its estimated fair value. The current Operating Margin % is 111.85% and 1401.3% above the Drug Manufacturers industry median of 7.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Operating Margin % is 111.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your 